US Adalimumab Outlook Brightens At Mid-Point Of 2024

PBMs Face Increasing Pressure Over Suppressing Uptake For Humira Biosimilars

 
• By David Wallace
  
Chart showing trending up in 2024
Uptake is beginning to ramp up for US adalimumab biosimilars in 2024 • Source: Shutterstock
In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Market Intelligence

More from In Vivo